Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-Step Haploidentical HSCT for High-Risk Hematologic Malignancies
NCT01982682Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in hematologic malignancy, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2013; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT01982682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01982682.